AIMS: To assess the impact of the UK Medicines and Healthcare products Regulatory Authority (MHRA) warning in December 2003 not to prescribe selective serotonin reuptake inhibitor (SSRI) antidepressants, except fluoxetine, to under-18-year-olds. METHODS: Interrupted time series analysis of prescriptions (UK) and general hospital presentations for nonfatal self-poisoning (three centres in England) for 2000-2006. RESULTS: Following the MHRA warning in December 2003 there were significant decreases in prescribing of SSRI antidepressants (conservative estimate 51%) to young people aged 12-19 years. Surprisingly, this decrease also affected fluoxetine (conservative estimate 20%) and tricyclics (conservative estimate 27%). Nonfatal self-poisoning in this age group following the warning also declined significantly for SSRIs (conservative estimate 44%), but not for fluoxetine, tricyclic antidepressants, or all drugs and other substances. Rates of nonfatal self-harm did not change significantly over the study period. CONCLUSIONS: The reduction in both prescribing and self-poisoning with SSRI antidepressants (except fluoxetine) following the MHRA warning is in keeping with reduced availability of these drugs. There was some evidence of substitution from other SSRIs to fluoxetine for use in self-poisoning. Importantly, overall rates of nonfatal self-harm and self-poisoning did not change, indicating no substitution of method or increases in self-injury.
AIMS: To assess the impact of the UK Medicines and Healthcare products Regulatory Authority (MHRA) warning in December 2003 not to prescribe selective serotonin reuptake inhibitor (SSRI) antidepressants, except fluoxetine, to under-18-year-olds. METHODS: Interrupted time series analysis of prescriptions (UK) and general hospital presentations for nonfatal self-poisoning (three centres in England) for 2000-2006. RESULTS: Following the MHRA warning in December 2003 there were significant decreases in prescribing of SSRI antidepressants (conservative estimate 51%) to young people aged 12-19 years. Surprisingly, this decrease also affected fluoxetine (conservative estimate 20%) and tricyclics (conservative estimate 27%). Nonfatal self-poisoning in this age group following the warning also declined significantly for SSRIs (conservative estimate 44%), but not for fluoxetine, tricyclic antidepressants, or all drugs and other substances. Rates of nonfatal self-harm did not change significantly over the study period. CONCLUSIONS: The reduction in both prescribing and self-poisoning with SSRI antidepressants (except fluoxetine) following the MHRA warning is in keeping with reduced availability of these drugs. There was some evidence of substitution from other SSRIs to fluoxetine for use in self-poisoning. Importantly, overall rates of nonfatal self-harm and self-poisoning did not change, indicating no substitution of method or increases in self-injury.
Authors: Robert J Valuck; Anne M Libby; Heather D Orton; Elaine H Morrato; Richard Allen; Ross J Baldessarini Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: Robert D Gibbons; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; Joëlle A Erkens; Ron M C Herings; J John Mann Journal: Am J Psychiatry Date: 2007-09 Impact factor: 18.112
Authors: Keith Hawton; Helen Bergen; Deborah Casey; Sue Simkin; Ben Palmer; Jayne Cooper; Nav Kapur; Judith Horrocks; Allan House; Rachael Lilley; Rachael Noble; David Owens Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2007-05-21 Impact factor: 4.328
Authors: Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112
Authors: Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol Journal: Drug Saf Date: 2012-05-01 Impact factor: 5.606
Authors: Keith Hawton; Helen Bergen; Keith Waters; Jennifer Ness; Jayne Cooper; Sarah Steeg; Navneet Kapur Journal: Eur Child Adolesc Psychiatry Date: 2012-03-25 Impact factor: 4.785
Authors: Paul Acheampong; Gill Cooper; Behshad Khazaeli; David J Lupton; Sue White; Margaret T May; Simon H L Thomas Journal: Br J Clin Pharmacol Date: 2013-12 Impact factor: 4.335
Authors: Anne E Rhodes; Jennifer Bethell; Corine Carlisle; Rhonda J Rosychuk; Hong Lu; Amanda Newton Journal: Can J Psychiatry Date: 2014-03 Impact factor: 4.356
Authors: Becky Mars; Jon Heron; David Kessler; Neil M Davies; Richard M Martin; Kyla H Thomas; David Gunnell Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2016-11-24 Impact factor: 4.328
Authors: Paul A Tiffin; Jose L Mediavilla; Helen Close; Adetayo S Kasim; Patrick Welsh; Lewis W Paton; James M Mason Journal: BMJ Open Date: 2019-08-07 Impact factor: 2.692